Handelsbanken Fonder
AUTL

Handelsbanken Fonder’s Autolus Therapeutics AUTL Stock Holding History

Handelsbanken Fonder’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-73,300
Closed -$114K – 1516
2025
Q1 		$114K Hold
73,300
– – ﹤0.01% 1516
2024
Q4 		$172K Buy
73,300
+17,300
+31% +$58.5K ﹤0.01% 1521
2024
Q3 		$203K Hold
56,000
– – ﹤0.01% 1492
2024
Q2 		$195K Buy
+56,000
New +$242K ﹤0.01% 1486

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Handelsbanken Fonder's AUTL Position: Q2 2025 in Review

Handelsbanken Fonder sold out of Autolus Therapeutics (AUTL) in Q2 2025, closing a stake of 73,300 shares — an estimated $114K sold.

Handelsbanken Fonder first reported a position in AUTL in Q2 2024 and held it in 4 quarters. The position peaked at $203K in Q3 2024. 94 funds tracked by Wall St. Rank hold AUTL as of Q2 2025.

  • Handelsbanken Fonder reported no remaining Autolus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Handelsbanken Fonder sold 73,300 Autolus Therapeutics shares in Q2 2025, an estimated $114K.
  • Handelsbanken Fonder first reported a position in Autolus Therapeutics in Q2 2024 and held it in 4 quarters.
  • Handelsbanken Fonder's Autolus Therapeutics position peaked at $203K in Q3 2024.
  • 94 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2025.

Based on Handelsbanken Fonder's 13F filing for Q2 2025, filed 12 Aug 2025.